Tweetovi
- Tweetovi, trenutna stranica.
- Tweetovi i odgovori
- Medijski sadržaj
Blokirali ste korisnika/cu @GileadSciences
Jeste li sigurni da želite vidjeti te tweetove? Time nećete deblokirati korisnika/cu @GileadSciences
-
Prikvačeni tweet
Statement from Gilead’s Chief Medical Officer Merdad Parsey: “Gilead is working closely with global health authorities to respond to the novel coronavirus (2019-nCoV) outbreak through the appropriate experimental use of our investigational compound."
Prikaži ovu nitHvala. Twitter će to iskoristiti za poboljšanje vaše vremenske crte. PoništiPoništi -
Hvala. Twitter će to iskoristiti za poboljšanje vaše vremenske crte. PoništiPoništi
-
“Gilead is focused on contributing our antiviral expertise and resources to help patients and communities fighting 2019-nCoV.” Read more: https://bit.ly/37N6Osq .
Prikaži ovu nitHvala. Twitter će to iskoristiti za poboljšanje vaše vremenske crte. PoništiPoništi -
Sandra Horning, MD, joins Gilead Sciences’ Board of Directors. Read more: https://bit.ly/3aSCm26 .
Hvala. Twitter će to iskoristiti za poboljšanje vaše vremenske crte. PoništiPoništi -
Gilead Sciences proslijedio/la je Tweet
Today the Marketing Authorization Application for our second
#CARTcell therapy was validated for review by the European Medicines AgencyHvala. Twitter će to iskoristiti za poboljšanje vaše vremenske crte. PoništiPoništi -
We are proud to take part in
#CCCongress20 alongside so many inspiring patients, healthcare professionals and other researchers working to improve the lives of those with#Crohns and#ulcerativecolitis.pic.twitter.com/tAeHam9dNi
Hvala. Twitter će to iskoristiti za poboljšanje vaše vremenske crte. PoništiPoništi -
We’re proud to share that, for the third consecutive year, we’ve earned a 100% score on the
@HRC Corporate Equality Index. Learn more about the annual survey, which aims to advance best practices for LGBTQ workplace inclusion: http://hrc.org/cei .#CEI2020https://twitter.com/HRC/status/1219643124970086400 …Hvala. Twitter će to iskoristiti za poboljšanje vaše vremenske crte. PoništiPoništi -
Chairman & CEO Daniel O'Day spoke at
#JPM20 this morning about Gilead's next chapter. Read more about what he had to say: http://bit.ly/30hqyS9 .pic.twitter.com/oXbyrqP4GG
Hvala. Twitter će to iskoristiti za poboljšanje vaše vremenske crte. PoništiPoništi -
Gilead announces licensing of The Rockefeller University’s portfolio of broadly neutralizing antibodies (bNAbs) against HIV: https://bit.ly/2t0YaaH .
Hvala. Twitter će to iskoristiti za poboljšanje vaše vremenske crte. PoništiPoništi -
Our team in Korea celebrated the holiday season last month by hosting its annual Gilead Hope Gallery. The art auction raised money for the Multicultural Family Support Center, an NGO that provides support services to people in need in Korea.pic.twitter.com/smOcfvn6kG
Hvala. Twitter će to iskoristiti za poboljšanje vaše vremenske crte. PoništiPoništi -
To celebrate the holidays, our employees around the world organized donation drives, volunteer events and other activities to support their local communities. Thank you to everyone who donated. We wish you and your loved ones a happy and healthy holiday season!pic.twitter.com/c8Zt3AVvXW
Hvala. Twitter će to iskoristiti za poboljšanje vaše vremenske crte. PoništiPoništi -
Gilead and Eisai announce co-promotion agreement for investigational rheumatoid arthritis treatment in Japan: https://bit.ly/2EMYnk3 .
Hvala. Twitter će to iskoristiti za poboljšanje vaše vremenske crte. PoništiPoništi -
China National Medical Products Administration approves Gilead’s single-tablet regimen for people with chronic
#HCV infection who require re-treatment. Learn more: https://bit.ly/34Ilbft .Hvala. Twitter će to iskoristiti za poboljšanje vaše vremenske crte. PoništiPoništi -
Gilead files NDA for investigational treatment of
#rheumatoidarthritis: https://bit.ly/2Z67jud .Hvala. Twitter će to iskoristiti za poboljšanje vaše vremenske crte. PoništiPoništi -
Today we announced topline results from the Phase 2 ATLAS study in
#NASH: https://bit.ly/38H3OPf .Hvala. Twitter će to iskoristiti za poboljšanje vaše vremenske crte. PoništiPoništi -
Gilead Sciences proslijedio/la je TweetHvala. Twitter će to iskoristiti za poboljšanje vaše vremenske crte. PoništiPoništi
-
Last week we held our annual HIV Age Positively conference in London. Congratulations to the 2019 grant recipients, whose innovative ideas will improve the lives of all people aging with
#HIV. Learn more: http://bit.ly/2rypRHd .#HIVAP2019pic.twitter.com/rX1zaXQRsX
Hvala. Twitter će to iskoristiti za poboljšanje vaše vremenske crte. PoništiPoništi -
Gilead Sciences proslijedio/la je Tweet
We’re here at
#ASH19 sharing our#celltherapy research in hematologic malignancies.#bloodcancerpic.twitter.com/NkgsPg5wiu
Hvala. Twitter će to iskoristiti za poboljšanje vaše vremenske crte. PoništiPoništi -
Gilead Sciences proslijedio/la je Tweet
We’re excited to share our survival data at three years for
#CARTcell therapy today at#ASH19. https://bit.ly/2PlN0og pic.twitter.com/uDW3D77LoX
Hvala. Twitter će to iskoristiti za poboljšanje vaše vremenske crte. PoništiPoništi -
We are proud to be recognized by
@HACRORG as a 5 Star Company in their Corporate Inclusion Index. Learn more about HACR’s efforts to advance Hispanic inclusion and help further diversity in the workplace: http://www.hacr.org/ .#HACRresearchpic.twitter.com/xftqIPCeqb
Hvala. Twitter će to iskoristiti za poboljšanje vaše vremenske crte. PoništiPoništi
Čini se da učitavanje traje već neko vrijeme.
Twitter je možda preopterećen ili ima kratkotrajnih poteškoća u radu. Pokušajte ponovno ili potražite dodatne informacije u odjeljku Status Twittera.